Grail sees Q3 sales jump, eyes Q1 for FDA Galleri PMA submission
Grail saw a sharp rise in third-quarter sales as it outlined a firmer FDA submission date for its Galleri cancer blood test. The California company posted a 26% year-over-year increase…
